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Epidermal growth factor receptor mutation in adenosquamous carcinoma:
A step forwardLung cancer is the most common cause of cancer death in
the world. Before the millennium, physicians usually classified
lung cancer into nonsmall-cell lung cancer (NSCLC) and
small-cell lung cancer (SCLC) when newly diagnosed lung
cancer patients were about to receive specific treatment. The
World Health Organization (WHO) proposed a new schema of
lung tumors that has been the foundation for lung cancer
classification and treatment since 2004.1 This classification
system included squamous cell carcinoma, small cell carci-
noma, adenocarcinoma, large cell carcinoma, adenosquamous
carcinoma, sarcomatoid carcinoma, carcinoid tumor, and
salivary gland tumors. The most common histologic type is
adenocarcinoma. Most of the remaining cases are squamous
cell, small cell, or large cell carcinomas, followed by rare
types of lung cancer that make up a small minority of cases. It
was also during 2004 that tumor epidermal growth factor
receptor (EGFR) activating mutations were found to be
responsible for the responsiveness of NSCLC to EGFR-
tyrosine kinase inhibitor (TKI) treatment.2,3
Since both EGFR mutations and ALK rearrangements are
found mainly in adenocarcinoma, a new proposal for pulmo-
nary adenocarcinoma classification was put forth by a multi-
disciplinary expert panel in 2011 to improve classification,
prognosis, and treatment evaluation.4 Thereafter, driver
oncogene identification for targeted therapy against advanced
stage NSCLC has become the most important issue in the
modern era of pulmonary oncology, including both adeno-
carcinoma and squamous cell carcinoma.5 Among these
oncogenes, the most frequently identified driver oncogene
mutations in Asian populations are EGFR mutations, and in
Caucasian populations, k-RAS mutation.5,6
A recent study by Bai et al revealed the genetic hetero-
geneity of EGFR mutations in intratumor tissue samples.7 A
total of 1331 tumor foci were fractionated from 42 patients
with tumor EGFR mutations. Samples from 26 patients con-
sisted of cells with both wild-type and mutated EGFR, with
the proportion of EGFR-mutant cells ranging from 30% to
90%. Another recent study of whole-genome and tran-
scriptome sequencing of tumor and adjacent normal tissue
samples from 17 NSCLC patients identified 3726 point
mutations and more than 90 indels in the coding sequence,
with the average mutation frequency more than 10-fold higher1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.05.008in smokers than in never-smokers. Deep digital sequencing
revealed diverse clonality patterns in these tumors.8 Thus,
tumor genetic heterogeneity is complex and frequently leads
to treatment failure, even in patients with treatable activating
driver oncogenes such as mutated EGFR.
Adenosquamous carcinomas are defined as tumors com-
prised of more than 10% malignant glandular and squamous
components. The mixed histology probably represents the
well-recognized heterogeneity of lung cancers, rather than a
prognostically distinct subset.9 The reported incidence of
adenosquamous carcinoma ranges from 0.4% to 4% of all lung
cancers. Song et al in this issue of the Journal of the Chinese
Medical Association reported on the “Therapeutic efficacy of
gefitinib and erlotinib in patients with advanced lung ade-
nosquamous carcinoma”.10 They found 13 of 49 (26.5%)
adenosquamous carcinoma patients responded to EGFR-TKI
treatment, and seven of 21 patients who had adequate speci-
mens for tumor EGFR DNA sequence analysis had EGFR
activating mutations. This retrospective study found EGFR-
TKI is an effective treatment for adenosquamous carcinoma.
They also reported that the frequency of EGFR mutations and
the clinical characteristics of the EGFR mutants in adenos-
quamous carcinoma were similar to those of Asian patients
with adenocarcinoma. With the exception of some case reports
presented at medical meetings, this is the first report to focus
on the frequency of EGFR mutations, the clinical character-
istics, and the efficacy of EGFR-TKI in treating adenosqu-
amous carcinoma. Two important messages emerge from this
article. First, in terms of treatment benefits, it always neces-
sary to check the tumor EGFR mutation status of patients with
adenosquamous carcinoma, and EGFR-TKI treatment given
when activating mutations are found. Second, patients with
adenosquamous carcinoma who had tumor EGFR activating
mutations benefitted from EGFR-TKI treatment similar to
adenocarcinoma patients with EGFR activating mutations.
Future work in the area of adenosquamous carcinoma
should focus on the following: Do EGFR mutations occur
purely in the adenocarcinoma component or in both the ade-
nocarcinoma and squamous cell carcinoma components? Are
the residual tumors after EGFR-TKI treatment purely of the
squamous cell component or still of the adenosquamous
component? Since the clinical characteristics and EGFRhinese Medical Association. All rights reserved.
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patients, another issue is whether the acquired EGFR-TKI
resistance mechanism is also similar to that of adenocarci-
noma. As seen here, many questions remain unanswered, and
further study is needed.References
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